Cavernoma: Bleeding Risk, MRI Diagnosis, and Surgery

A cavernoma is a cluster of abnormal blood vessels in the brain or spinal cord, made up of thin-walled cavities filled with slow-moving blood. These lesions, also called cerebral cavernous malformations (CCMs), affect roughly half a percent of the general population and account for up to 15 percent of all blood vessel malformations inside the skull. Many people live their entire lives without knowing they have one, but for others, a cavernoma can bleed, trigger seizures, or press on surrounding tissue in ways that demand medical attention.

What a Cavernoma Looks Like Under the Microscope

Unlike normal blood vessels, the channels inside a cavernoma lack the protective layers of smooth muscle and elastic fibers that give healthy arteries and veins their strength. Instead, they are lined by a single thin layer of cells, and there is no normal brain tissue sandwiched between the vascular spaces. Over time, the walls of these channels tend to thicken with scar-like collagen deposits. The result is a structure sometimes compared to a mulberry or a cluster of small bubbles, prone to slow leaks because its walls are inherently fragile.

Sporadic Versus Familial Forms

Most cavernomas occur as a single, one-off event with no clear family pattern. These sporadic cases are thought to arise from random mutations that affect the lining cells of blood vessels during a person’s lifetime. But in a meaningful minority of cases, cavernomas run in families. The familial form follows an autosomal dominant inheritance pattern, meaning a child has a 50 percent chance of inheriting the condition from an affected parent. Familial cases are caused by a loss-of-function mutation in one of three genes: CCM1 (also called KRIT1), CCM2 (Malcavernin), or CCM3 (PDCD10).¹ A telltale sign of the familial form is having multiple cavernomas scattered throughout the brain and spinal cord, rather than just one.

Of the three gene mutations, CCM3 tends to carry the worst prognosis. Patients with CCM3 mutations often develop lesions earlier in life and experience more aggressive disease. The proteins encoded by all three genes normally work together as a complex that helps keep the junctions between cells lining blood vessels tight and stable. When the complex fails, a signaling pathway involving a protein called RhoA and its partner ROCK becomes overactive, leading to the formation of stress fibers that pull endothelial junctions apart and make the vessel walls leaky.²

How Cavernomas Cause Symptoms

Many cavernomas are discovered incidentally when someone has a brain scan for an unrelated reason. When they do cause problems, the symptoms depend largely on where the lesion sits and whether it has bled.

Seizures are the most common symptom for cavernomas located in the cerebral hemispheres. Even small, repeated leaks from the malformation deposit hemosiderin, a breakdown product of blood, into the surrounding brain tissue. Hemosiderin generates free radicals and disrupts normal nerve cell signaling, essentially irritating the neighboring neurons into misfiring.³ This is why surgical teams removing a cavernoma to control seizures often try to take out the surrounding hemosiderin-stained tissue as well. Patients whose surgeons successfully removed all that discolored tissue had better long-term seizure control than those in whom some hemosiderin was left behind.⁴

Cavernomas in the brainstem present a very different clinical picture. Because the brainstem is packed with vital nerve pathways controlling movement, sensation, eye coordination, swallowing, and breathing, even a small bleed can cause dramatic neurological deficits. Repeated hemorrhages from brainstem malformations are more common than from cavernomas elsewhere and typically produce new deficits each time.⁵

How Often Do Cavernomas Bleed

The bleeding risk is one of the most important questions for anyone living with a cavernoma, and the answer varies dramatically depending on location and history. A large meta-analysis pooling 25 studies estimated the annual hemorrhage rate at roughly 0.3 percent per year for lesions outside the brainstem and about 2.8 percent per year for brainstem lesions.⁶ Those numbers may sound reassuring, but the picture changes sharply after a first bleed. The same analysis found that the risk of a second hemorrhage was dramatically higher: about 6.3 percent per year for non-brainstem lesions and a striking 32.3 percent per year for brainstem cavernomas that had already bled once.⁷

This steep rise in rebleeding risk is a central factor in treatment decisions. A cavernoma in a non-critical area that has never bled can often be watched with periodic scans. A brainstem lesion that has already hemorrhaged twice faces odds high enough that active intervention becomes much harder to defer.

Diagnosing a Cavernoma on MRI

MRI is the gold standard for detecting cavernomas. On standard sequences, a typical cavernoma appears as a “popcorn” or mixed-signal lesion, often surrounded by a dark ring of hemosiderin. But not all cavernomas show up equally well on every MRI sequence. Susceptibility-weighted imaging (SWI) is significantly more sensitive than older gradient-echo sequences at picking up these lesions, especially the tiny ones that might otherwise be missed.⁸⁹ This matters most for people with the familial form, who may have dozens of small lesions scattered throughout the brain. If you have a family history and are being screened, it is worth confirming that the MRI protocol includes SWI.

One diagnostic pitfall worth knowing about: not everything that looks like a hemorrhagic cavernoma on a first scan actually is one. Tumor metastases can sometimes mimic the appearance of a bleeding cavernoma. Compared to true cavernomas, these mimics tend to occur in older patients, are more likely to show contrast enhancement on the initial MRI, and are much more likely to have persistent surrounding swelling on follow-up imaging.¹⁰ A history of cancer elsewhere in the body is a strong red flag. When there is any doubt, a follow-up scan within a few months can help clarify whether the lesion is behaving like a cavernoma or something else.

The Link to Developmental Venous Anomalies

Cavernomas frequently appear alongside another vascular finding called a developmental venous anomaly (DVA), which is essentially a variant drainage vein. Research suggests that DVAs may actually play a role in causing some sporadic cavernomas to form in the first place, and their presence has been associated with a somewhat more aggressive natural history, including a higher chance of hemorrhage and lesion growth.¹¹

Despite that reputation, a study of 183 surgical patients found that having an associated DVA did not actually lead to worse outcomes after surgery. Patients with a coexisting DVA had slightly better neurological status both before and after their operation compared to those without one, and recurrence rates were negligible in both groups.¹² One critical surgical rule, though: the DVA itself should never be removed. It serves as the normal drainage pathway for surrounding brain tissue, and cutting it can cause a venous infarct, a type of stroke caused by blocked drainage.¹³

Surgical Treatment and What to Expect

Surgery to remove a cavernoma is the most definitive treatment available. For lesions in non-critical (“non-eloquent”) areas of the brain, the results are generally excellent: the malformation is taken out, the risk of future hemorrhage drops to near zero, and most patients recover well. Even for lesions in eloquent areas (regions governing speech, movement, or sensation), surgery can still be appropriate. A long-term follow-up study found that the majority of surgical complications in eloquent-area cases were transient, and about 85 percent of patients recovered to their preoperative level or better. Quality of life after eloquent-area surgery was comparable across most measures, though patients tended to perceive their general health as somewhat lower than population norms.¹⁴

Brainstem surgery carries higher stakes. In a series of 52 patients who underwent microsurgical removal of brainstem cavernomas, more than half experienced new neurological deficits right after surgery, but most of those improved over time. Permanent new deficits occurred in about 19 percent of patients, and the mortality rate was under 2 percent.¹⁵ The surgical approach mattered: patients whose lesion could be accessed through a specific route along the side of the brainstem had significantly lower rates of permanent deficit than those requiring other approaches.

Radiosurgery as an Alternative

For cavernomas that are too deep or too risky to remove with open surgery, Gamma Knife radiosurgery is sometimes offered. This technique delivers a focused beam of radiation to the lesion without an incision. It does not physically remove the cavernoma but appears to reduce future bleeding risk over time. In one study of 45 patients with symptomatic brainstem cavernomas, the annual hemorrhage rate dropped from about 40 percent before treatment to 3.3 percent at two years and 1.5 percent at five years, with only one patient developing a radiation-related complication.¹⁶

Other studies have broadly confirmed these trends, showing that after radiosurgery for brainstem cavernomas, annual hemorrhage rates tend to fall substantially within the first two years and remain lower beyond that window. Radiation-related side effects occur in roughly 3 to 12 percent of patients depending on the series.¹⁷ Radiosurgery remains somewhat controversial for cavernomas compared to its well-established role in other brain conditions, but for deeply located lesions where surgery would carry unacceptable risk, it fills an important gap.

Cavernomas in the Spinal Cord

While brain cavernomas get most of the attention, these malformations can also occur in the spinal cord. Spinal cavernomas most commonly sit in the thoracic segment and tend to present with motor and sensory deficits, often alongside bowel or bladder problems.¹⁸ The annual hemorrhage risk for spinal cavernomas appears similar to brain cavernomas at around 2 percent per patient-year, but the rebleeding rate jumps considerably after a first hemorrhage.¹⁹

Surgical removal is generally favored when symptoms are significant and the lesion can be completely taken out. Timing matters: patients who had surgery within three months of symptom onset tended to do better than those who waited longer.²⁰ Lesions on the back surface of the cord are more accessible and carry better outcomes than those buried deeper on the front or sides. Across a systematic review of spinal cavernoma surgeries, about 37 percent of patients improved, 56 percent remained stable, and 7 percent worsened.²¹

Pregnancy and Hormonal Considerations

A common concern for women of childbearing age with a known cavernoma is whether pregnancy increases the risk of hemorrhage. Early case reports raised that worry, and it seems intuitive that the hormonal and circulatory changes of pregnancy might destabilize a fragile vascular lesion. However, more recent and better-designed studies have not confirmed an elevated risk. Prospective data suggest that pregnancy does not increase the chance of hemorrhage and that vaginal delivery is safe in appropriate candidates.²² A separate study found the hemorrhage rate during pregnancy to be essentially the same as during non-pregnant years, with a relative risk near 1.0.²³

Exogenous hormones are a different matter. One multicenter study found that women using hormone replacement therapy or oral contraceptives had a meaningfully higher hemorrhage rate than those who were not, though the data are still limited. Current expert opinion leans toward discouraging estrogen-based contraceptives and hormone replacement therapy in women with cavernomas, especially those with deep-seated lesions or a prior bleed.²⁴

Living with a Cavernoma and Quality of Life

The psychological burden of a cavernoma diagnosis is real and often underappreciated. Even people with asymptomatic, untreated cavernomas report reduced quality of life compared to the general population, along with heightened anxiety.²⁵ Living with the knowledge that you have a blood vessel abnormality in your brain that could bleed at any time creates a background of uncertainty that standard neurological assessments do not capture.

For patients with cavernoma-related epilepsy being managed with medication rather than surgery, the impact is even more pronounced. Research has found significantly lower quality of life and higher anxiety levels in this group, affecting both physical and mental well-being. Strikingly, whether or not seizure medication was effective at controlling seizures did not seem to restore quality of life, anxiety, or depression scores to normal levels.²⁶ In the familial form, prior hemorrhage was linked to worse anxiety, fatigue, and physical functioning, while headaches were associated with worse depression, fatigue, and sleep disturbance.²⁷ These findings underscore that treating a cavernoma is not just about preventing the next bleed; psychological support and mental health screening deserve a place in the care plan.

Drug Therapies on the Horizon

There are currently no approved medications to prevent cavernoma growth or bleeding, but several candidates are moving through the research pipeline. The most advanced is propranolol, a beta-blocker widely used for other conditions. A phase 2 pilot trial in patients with the familial form found that those taking propranolol in addition to standard care had a lower rate of symptomatic brain hemorrhage or new neurological deficits than those receiving standard care alone.²⁸ The results were promising enough to justify larger, adequately powered trials, though the study itself was small and cannot be considered definitive on its own.

Other approaches in preclinical or early clinical stages include drugs that block the overactive RhoA/ROCK signaling pathway (fasudil, statins, and the specific inhibitor NRL-1049), as well as a compound called REC-994, a superoxide dismutase mimetic designed to neutralize oxidative stress in lesion tissue. REC-994 is currently in a phase 2 clinical trial evaluating its safety and potential effectiveness.²⁹ The field is notably more active than it was a decade ago, but a widely available medical therapy remains years away.

The Gut Microbiome Connection

One of the more unexpected discoveries in cavernoma research has come from the gut. Studies in mice showed that a receptor on the surface of blood vessel cells (TLR4) responds to molecules produced by bacteria in the gut, and that this signaling can accelerate cavernoma formation in animals predisposed to the condition. Germ-free mice, which have no gut bacteria at all, were protected from forming cavernomas, and a single course of antibiotics permanently changed how susceptible mice were to lesion development.³⁰ In humans, genetic variants that increase the activity of this same receptor have been associated with a higher number of lesions.

Further work has confirmed that patients with cavernomas show differences in their gut bacterial composition compared to healthy controls, and that the health of the gut barrier may influence disease progression.³¹ The research connecting CCM3 mutations specifically to a gut-brain disease axis has added another layer, suggesting that the most aggressive genetic form of the disease may be particularly sensitive to gut-derived inflammatory signals.³² No one is recommending probiotics or dietary changes as a treatment for cavernomas yet, but the microbiome angle has opened a genuinely new way of thinking about why some people develop more lesions than others and what might eventually be done about it.

Cavernomas in Children

Cavernomas in children deserve special mention because they tend to behave more aggressively than in adults. Pediatric cases carry a higher annual hemorrhage rate and are more likely to present with acute symptoms like seizures, sudden weakness, or visible bleeding on imaging rather than being found incidentally.³³ Children with the familial form, especially those carrying CCM3 mutations, may develop lesions very early in life. Genetic testing in pediatric patients with multiple cavernomas can help guide family screening and long-term surveillance planning, particularly because siblings and parents may carry the same mutation without yet knowing it.